AOP Health Presents New Findings Regarding Consistent Hemato

AOP Health announced new results on ropeginterferon alfa-2b (BESREMi®) from its clinical study CONTINUATION-PV in patients with polycythaemia vera (PV), a rare blood cancer. Professor Heinz Gisslinger

Related Keywords

Austria , Vienna , Wien , Kurt Krejcy , Lylia Sivcheva , Halyna Pylypenko , Petr Dulicek , Pencho Georgiev , Vera Yablokova , Dorota Krochmalczyk , Robert Kralovics , Jean Jacques Kiladjian , Arpad Illes , Miklos Egyed , Christoph Klade , Hansc Hasselbalch , Polycythaemia Vera , Heinz Gisslinger , European Haematology Association , European Hematology Association , Aop Health , Study Group , Pharmaceuticals Gmb , University Of Vienna , Health Group , Medical University , Liana Gercheva Kyuchukova , Victoria Empson , Annual Meeting June , Pharmaceuticals Gmbh , Middle East , Gefallene Big Techs , Health , Presents , Findings , Egarding , Consistent , Aematologic , Response , Patients , Ith , Olycythaemia , Vera ,